James Engelhart, Chief Financial Officer at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 538 shares at $29.60 ($16K) on 2018-02-21, disclosed to the SEC on 2018-02-23.
Scheduled sale ($16k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BHVN | BUY | 2019-06-28 | $108K | — | Filing → |
| BHVN | SELL | 2018-05-30 | $175K | — | Filing → |
| BHVN | SELL | 2018-05-09 | $69K | — | Filing → |